Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00181779 · ClinicalTrials.gov registry record · Phase 4
Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar Disorder
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00181779: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00181779 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00181779, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is an open-labeled study of Aripiprazole, testing its efficacy in the treatment of mania in children and adolescents with Bipolar I, Bipolar II and Bipolar Spectrum Disorder over 8 weeks. This is an exploratory, pilot study, seeking to determine whether Aripiprazole is efficacious and well tolerated in the treatment of youth with pediatric bipolar and bipolar spectrum disorder. The study results will be used to generate hypotheses for a larger randomized controlled clinical trial with explicit hypotheses and sufficient statistical power.
Interventions
- DRUG aripiprazole (Abilify)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-02 |
| Est. Completion | 2006-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00181779
The ClinicalTrials.gov registry entry for NCT00181779 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aripiprazole (Abilify) is the first listed.
NCT00181779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00181779 about?
NCT00181779 is a clinical study titled "Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar Disorder". This is an open-labeled study of Aripiprazole, testing its efficacy in the treatment of mania in children and adolescents with Bipolar I, Bipolar II and Bipolar Spectrum Disorder over 8 weeks. This is an exploratory, pilot study, seeking to determine whether Aripiprazole is efficacious and well tole...
What is the current status of trial NCT00181779?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2003-02. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00181779?
The interventions under investigation include: aripiprazole (Abilify) (DRUG).
Who is sponsoring clinical trial NCT00181779?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.